In light of the recent approval of Nivolumab and Ipilimumab for metastatic NSCLC with PDL1 >1%, what is your preferred first line treatment option for a fit patient who is PDL1 positive (<50%) with no driver mutations?
Answer from: Medical Oncologist at Academic Institution
My preferred first line option for patients with advanced NSCLC and PDL1 TPS score of >1% and <50-% remains chemotherapy with immunotherapy. I prefer carboplatin- pemetrexed -pembrolizumab for nonsquamous and carboplatin-taxane-pembrolizumab for squamous cell NSCLC. I might consider Nivolumab ...
Comments
Medical Oncologist at Yuma Regional Medical Center Cancer Center I would add that patients who recurred after durva...
Medical Oncologist at University of Michigan Medical School Agree with @Shadia I. Jalal. I would use chemo-imm...
I would add that patients who recurred after durva...
Agree with @Shadia I. Jalal. I would use chemo-imm...